Shots:
- FLEX Vascular reported 12mos. results from the FLEX FIRST AV Registry at Charing Cross Symposium 2026, showing strong safety with 0% serious adverse events at 30 days & durable performance in hemodialysis access patients
- The study (n=130) demonstrated 40% primary patency in cephalic arch lesions & 100% secondary patency in AV grafts at 12mos., reducing reinterventions by ~1 per patient annually
- The FLEX Vessel Prep System uses a mechanical, no-drug, no-implant KEMIC approach to improve vessel compliance, supporting a differentiated strategy for vascular access interventions
Ref: PRnewswire| Image: FLEX Vascular| Press Release
Related News: Utepreva Launches Utepreva Endometrial Sampler to Support Early Diagnosis of Endometrial Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
